Amylyx reports Phase 3 success for avexitide in post-bariatric hypoglycemia

Amylyx announced a late-stage success for avexitide, a GLP-1 receptor antagonist, in a Phase 3 trial targeting post-bariatric hypoglycemia.

The trial results showed the drug achieved its primary efficacy goal, indicating it can reduce episodes of low blood sugar after bariatric surgery.

The win marks a strategic shift for Amylyx, which previously focused on ALS, and positions the company as a potential player in the GLP-1 therapeutic space.